Compare TULP & QNME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TULP | QNME |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Integrated Freight & Logistics |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 10.5M |
| IPO Year | 2026 | 2024 |
| Metric | TULP | QNME |
|---|---|---|
| Price | $2.31 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.4K | ★ 573.1K |
| Earning Date | 11-12-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.83 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,800,000.00 | $5,850,681.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 111.79 |
| 52 Week Low | $2.00 | $0.24 |
| 52 Week High | $4.99 | $1.40 |
| Indicator | TULP | QNME |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 33.15 |
| Support Level | $2.00 | N/A |
| Resistance Level | $2.50 | $0.43 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 53.09 | 2.36 |
Bloomia Holdings Inc is a specialty agricultural company focused on making and managing its ag investments in the U.S. and internationally. The Company is the majority owner of Bloomia, one of the largest producers of fresh-cut tulips in the United States.
Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.